{
    "clinical_study": {
        "@rank": "158281", 
        "brief_summary": {
            "textblock": "To compare the safety and effectiveness of fluconazole with that of placebo as maintenance\n      treatment for preventing the relapse of cryptococcal meningitis in patients with AIDS."
        }, 
        "brief_title": "A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients With AIDS", 
        "condition": [
            "Meningitis, Cryptococcal", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes", 
                "Meningitis", 
                "Meningitis, Cryptococcal"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Antiviral therapy (e.g., zidovudine).\n\n          -  Prophylaxis (including aerosolized pentamidine) for Pneumocystis carinii pneumonia\n             (PCP).\n\n        Concurrent Treatment:\n\n        Allowed:\n\n          -  Radiation therapy for mucocutaneous Kaposi's sarcoma.\n\n        Patients must be oriented to person, place, and time and able to give written informed\n        consent.\n\n          -  Patients must have had an acute episode of cryptococcal meningitis that was\n             documented by recovery and identification of cryptococcus from lumbar cerebrospinal\n             fluid (CSF) culture within 4 months of study entry.\n\n          -  Adequate therapy will consist of 6 - 16 weeks of treatment with amphotericin B alone,\n             amphotericin B + oral flucytosine, or a period of the combination followed by\n             amphotericin alone. Adequate regimens will include:\n\n          -  A minimum total amphotericin B dose of 2 grams as monotherapy.\n\n          -  6 weeks of flucytosine at 150 mg/kg/day (or levels of 20 to 100 mcg/ml demonstrated)\n             plus amphotericin B at an average daily dose of at least 0.3 mg/kg/day or to a total\n             dose of 1 gram.\n\n          -  After a shorter period of the combination amphotericin/flucytosine therapy, an\n             additional Y grams of amphotericin B monotherapy will make therapy adequate where Y =\n             2 gm-(X weeks combination therapy / 3 weeks).\n\n          -  For example, a patient who received 3 weeks of combination followed by amphotericin\n             alone would need an additional 2 gm - 3 weeks/3 weeks = 1 gm of amphotericin B.\n\n          -  Patients need not be receiving amphotericin B at the time of randomization but must\n             begin study maintenance therapy within 3 weeks of cessation of primary amphotericin B\n             therapy.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Antiviral therapy (e.g., zidovudine (AZT)).\n\n          -  Prophylaxis (including aerosolized pentamidine) for Pneumocystis carinii pneumonia\n             (PCP).\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  Clinical evidence of acute or chronic meningitis based upon any etiology other than\n             cryptococcosis.\n\n          -  History of allergy or intolerance of imidazoles, azoles, or amphotericin B.\n\n          -  Moderate or severe liver disease.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Intrathecal amphotericin B.\n\n          -  Coumarin-type anticoagulants.\n\n          -  Oral hypoglycemics.\n\n          -  Barbiturates.\n\n          -  Phenytoin.\n\n          -  Immunostimulants.\n\n          -  Investigational drugs or approved (licensed) drugs for investigational indications.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Lymphocyte replacement.\n\n        Patients with the following are excluded:\n\n          -  Clinical evidence of acute or chronic meningitis based upon any etiology other than\n             cryptococcosis.\n\n          -  History of allergy or intolerance of imidazoles, azoles, or amphotericin B.\n\n          -  Moderate or severe liver disease defined by specific lab values.\n\n          -  Inability to take oral medications reliably.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Intrathecal amphotericin B.\n\n          -  Coumarin-type anticoagulants.\n\n          -  Oral hypoglycemics.\n\n          -  Barbiturates.\n\n          -  Phenytoin.\n\n          -  Immunostimulants.\n\n          -  Investigational drugs or approved (licensed) drugs for investigational indications.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Lymphocyte replacement."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002294", 
            "org_study_id": "012A", 
            "secondary_id": "056-114A"
        }, 
        "intervention": {
            "intervention_name": "Fluconazole", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Fluconazole"
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Meningitis", 
            "Cryptococcosis", 
            "Fluconazole", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "Dr Robert Larsen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92668"
                    }, 
                    "name": "UCI Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92103"
                    }, 
                    "name": "UCSD"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sherman Oaks", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91403"
                    }, 
                    "name": "Dr Paul Rothman"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford Univ School of Medicine"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Double Blind Placebo Controlled Study of Fluconazole (UK-49,858) for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002294"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 1989"
    }, 
    "geocoordinates": {
        "Dr Paul Rothman": "34.149 -118.451", 
        "Dr Robert Larsen": "34.052 -118.244", 
        "Stanford Univ School of Medicine": "37.429 -122.169", 
        "UCI Med Ctr": "33.788 -117.853", 
        "UCSD": "32.715 -117.157"
    }
}